



RCE/ew
\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/729,704
APPLICANTS : Guenzler-Pukall, et al.
FILING DATE : 04 December 2003
GROUP ART UNIT : 1654
EXAMINER : Roy R. Teller
DOCKET NO. : FP0602.1 US
TITLE : TREATMENT OF DIABETES

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

TRANSMITTAL

The following items accompany this Transmittal:

1. Return Receipt Postcard
2. Request for Continued Examination (2pgs)
3. Amendment & Reply Under 37 CFR §1.114 (10pgs)
4. Copy of Petition for Extension of Time (filed 13 Oct 2010) (1pg)
5. Declaration of Volkmar Guenzler-Pukall, M.D. (4pgs)
6. Exhibit A: CV of Volkmar Guenzler-Pukall, M.D. (11pgs)
7. Exhibit B: Wenger (J Exp Biol)(2000) 1253-1263

Applicant claims small entity status under 37 C.F.R. 1.27.

The Commissioner is hereby authorized to charge any fees necessary in this communication to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US.

Please call Applicant's representative at 415-978-1748 with any questions regarding this communication or the above-identified application.

Respectfully submitted,

Date: 22 October 2010

By:

Paul Borchardt, Ph.D.
Reg. No. 53,999

Reg No. 54,575

FibroGen, Inc.
409 Illinois Street
San Francisco, CA 94158
Main: 415-978-1200
Direct: 415-978-1748
Facsimile: 415-978-1917
pborchardt@fibrogen.com

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 22 October 2010.

Name: Michael Moores

Signature: [Signature]